RxDoctor Payments Data

Aditya Patel, MD

Interventional Pain Medicine · Hackensack, NJNPI 1134410236

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 154 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Abbott accounts for 72.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $2,712 and has fallen 93.3% since, to $180 in 2025.

$8,230in general payments, 2019–2025

Across 154 payments — averaging $53.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$6K
  • Nevro Corp.$676
  • Boston Scientific$389
  • Globus Medical$291
  • Vertos Medical, Inc.$205
  • Foundation Fusion Solutions, LLC$194
  • plus $483 from 14 others

What the payments were for

  • Food & beverage$8,230100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,230 in reported general payments places this provider in the 75th percentile of 82 interventional pain medicine providers in New Jersey.

See all interventional pain medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$67,187
Medicare patients
150
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium59$5,204
Meloxicam230$949
Methylprednisolone127$936
Tizanidine Hcl74$672
Cyclobenzaprine Hcl216$552
Ibuprofen42$318
Gabapentin33$299
Nabumetone22$287
Pregabalin25$251
Tramadol Hcl47$138
Morphine Sulfate ErMorphine Sulfate11$123
Cephalexin12$111
Naproxen12$61

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →